^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | benmelstobart (APL-502) (PD-L1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
37P - PD-L1 on the endothelium of micrangium inside tumor: a novel predictor for the efficacy of anti-angiogenesis (anlotinib) plus anti-PD-L1 (TQ-B2450) ?
Published date:
12/02/2021
Excerpt:
The relationship between the expression of PD-L1 and clinicopathological characteristics was analyzed. Survival curves between groups of high and low PD-L1 expression were compared by Log-rank method….In patients with high expression both on vascular endothelial cells and tumor cells who experienced TQ-B2450 alone, the mPFS was significantly shorter than that of patients receiving anlotinib plus TQ-B2450 (89 days vs 246 days, P=0.002).
